Malaria is still a prevalent parasite illness throughout the globe, causing RBC infection and splenomegaly. To effectively diagnose malaria and elucidate its pathologic alterations, new specialized biomarkers such as MicroRNAs (miRNAs) are being created. The goal of this study was to look at changes in Plasmodium vivax plasma miRNA indicators in malaria patients in Chabahar, Iran. We took blood samples from 20 people for the current descriptiveanalytical investigation, which took place in 2018. The plasma levels of miR-145, miR-155, miR-191, and miR-223-3p were measured using real-time quantitative polymerase chain reaction (RT-qPCR). Patients with P. vivax had plasma levels of miR-223, miR-145, and miR-155 that were 5.6, 16.9, and 1.7 times greater than healthy people, according to the 2-CT technique of Realtime PCR. The expressions of all three miRNAs were substantially higher in malaria patients compared to controls (P0.05). Although the difference was statistically insignificant, the expression of miR-191 was 1.405 times greater in malaria patients than in controls. P. vivax was discovered to alter host miRNAs such as miR-223, miR-145, and miR-155 in the current study. As a result, these tiny compounds proved to be biomarkers for detecting P. vivax malaria.
